This bill matters to voters because it directly addresses the high cost of prescription drugs by tackling a specific legal hurdle that can delay the availability of cheaper generic and biosimilar versions. Currently, complex patent laws, especially 'method of use' patents, can allow brand-name drug companies to extend their market exclusivity even after the core drug patent expires. This bill clarifies that generic manufacturers can market a drug for its non-patented uses without facing infringement lawsuits.

If this bill becomes law, it could significantly speed up the introduction of lower-cost generics and biosimilars, potentially saving patients and the healthcare system billions of dollars. If it doesn't pass, the current legal framework, which some argue brand-name companies use to 'evergreen' their patents and delay competition, would remain, continuing to contribute to higher drug costs for consumers.